Subcutaneous Epcoritamab in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma: Preliminary Phase 1/2 Results

被引：0
|
作者：
Linton, Kim M. [1 ,2 ]
Wahlin, Bjorn [3 ,4 ]
Leppa, Sirpa [5 ]
Morschhauser, Franck [6 ]
Elliott, Brian [7 ]
Liu, Tracy [7 ]
Stirner, Mariana Cota [8 ]
Abbas, Aqeel [7 ]
Falchi, Lorenzo [9 ]
机构：
[1] Christie NHS Fdn Trust, Manchester, Lancs, England
[2] Manchester Canc Res Ctr, Manchester, Lancs, England
[3] Karolinska Inst, Stockholm, Sweden
[4] Helsinki Univ Hosp, Ctr Comprehens Canc, Helsinki, Finland
[5] Univ Helsinki, Helsinki, Finland
[6] Univ Lille, CHU Lille, Lille, France
[7] Genmab, Princeton, NJ USA
[8] AbbVie, N Chicago, IL 60064 USA
[9] Mem Sloan Kettering Canc Ctr, Lymphoma Serv, New York, NY USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2022年 / 197卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
BSH22-PO53
引用
收藏
页码：94 / 94
页数：1
相关论文
共 50 条
  • [41] Lenalidomide in combination with rituximab is effective with manageable toxicity in a phase I/II study in relapsed/refractory mantle cell lymphoma
    Wang, M.
    Fayad, L.
    Hagemeister, F.
    Neelapu, S.
    Samuels, B.
    Samanigo, F.
    Pro, B.
    Yi, Q.
    Bell, N.
    Byrne, C.
    Weaver, P.
    Hartig, K.
    Knight, R.
    Zeldis, J.
    Kwak, L.
    Romaguera, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 174 - 174
  • [42] PHASE IIIB RANDOMIZED STUDY OF LENALIDOMIDE PLUS RITUXIMAB (R2) FOLLOWED BY LENALIDOMIDE VS. RITUXIMAB MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY NHL: ANALYSIS OF FOLLICULAR LYMPHOMA PATIENTS
    Burke, J. M.
    Andorsky, D. J.
    Yacoub, A.
    Melear, J.
    Coleman, M.
    Kolibaba, K.
    Brooks, H.
    Bitran, J.
    Fanning, S.
    Lansigan, F.
    Ricker, J. L.
    Foon, K.
    Llorente, M.
    Li, J.
    Sharman, J.
    HAEMATOLOGICA, 2017, 102 : 249 - 250
  • [43] Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial
    Kersten, Marie Jose
    Dreyling, Martin
    Linton, Kim M.
    Chitu, Dana
    Tonino, Sanne
    Kap, Marcel
    Liu, Roberto D.
    Chamuleau, Martine E. D.
    Visser, Hein P. J.
    De Jongh, Eva
    Marijt, Erik Waf
    Leijs, Maria B. L.
    Bilgin, Yavuz M.
    Duerig, Jan
    McKay, Pamela
    Snijders, Tjeerd J. F.
    Pettitt, Andrew
    Minnema, Monique C.
    Prange-Krex, Gabriele
    Cuijpers, Maria
    Boehmer, Lara H.
    Tick, Lidwine W.
    Florschuetz, Axel
    Silbermann, Matthijs
    Fijnheer, Rob
    Beeker, Aart
    Tolboom, Nelleke
    Mitea, Cristina
    Arens, Anne I. J.
    Zwezerijnen, Gerben J. C.
    Klapper, Wolfram
    Coupland, Sarah E.
    de Jong, Daphne
    Doorduijn, Jeanette K.
    Zijlstra, Josee M.
    BLOOD, 2022, 140 : 2283 - 2285
  • [44] Subcutaneous Epcoritamab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Preliminary Results from the Epcore CLL-1 Trial
    Kater, Arnon P.
    Christensen, Jacob Haaber
    Bentzen, Hans Herluf
    Niemann, Carsten Utoft
    Hutchings, Martin
    Chen, Jenny
    Rios, Marcia
    Palenski, Tammy
    Li, Tommy
    Mato, Anthony R.
    BLOOD, 2021, 138
  • [45] Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia
    Chavez, Julio C.
    Piris-Villaespesa, Miguel
    Dalia, Samir
    Powers, John
    Turba, Elyce
    Nodzon, Lisa
    Komrokji, Rami
    Sokol, Lubomir
    Locke, Frederick L.
    Lancet, Jeffrey
    Sotomayor, Eduardo M.
    Kharfan-Dabaja, Mohamed A.
    Pinilla-Ibarz, Javier
    LEUKEMIA RESEARCH, 2016, 47 : 78 - 83
  • [46] Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma
    Rubenstein, James L.
    Geng, Huimin
    Fraser, Eleanor J.
    Formaker, Paul
    Chen, Lingjing
    Sharma, Jigyasa
    Killea, Phoebe
    Choi, Kaylee
    Ventura, Jenny
    Kurhanewicz, John
    Lowell, Clifford
    Hwang, Jimmy
    Treseler, Patrick
    Sneed, Penny K.
    Li, Jing
    Wang, Xiaomin
    Chen, Nianhang
    Gangoiti, Jon
    Munster, Pamela N.
    Damato, Bertil
    BLOOD ADVANCES, 2018, 2 (13) : 1595 - 1607
  • [47] Preliminary Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma
    Herrera, Alex F.
    Bartlett, Nancy L.
    Ramchandren, Radhakrishnan
    Vose, Julie M.
    Moskowitz, Alison J.
    Feldman, Tatyana A.
    LaCasce, Ann S.
    Ansell, Stephen M.
    Moskowitz, Craig H.
    Fenton, Keenan
    Kato, Kazunobu
    Fong, Abraham
    Advani, Ranjana H.
    BLOOD, 2016, 128 (22)
  • [48] Obinutuzumab: A Review in Rituximab-Refractory or -Relapsed Follicular Lymphoma
    Dhillon, Sohita
    TARGETED ONCOLOGY, 2017, 12 (02) : 255 - 262
  • [49] Obinutuzumab: A Review in Rituximab-Refractory or -Relapsed Follicular Lymphoma
    Sohita Dhillon
    Targeted Oncology, 2017, 12 : 255 - 262
  • [50] Lenalidomide Plus Rituximab for Relapsed or Refractory Diffuse Large B-Cell, Follicular and Transformed Lymphoma: Final Data Analysis of a Phase 2 Trial
    Wang, Yucai
    Wagner-Bartak, Nicolaus
    Zhou, Shouhao
    Fowler, Nathan
    Dela Rosa, Maria Lourdes
    Zhao, Donglu
    Romaguera, Jorge E.
    Neelapu, Sattva S.
    Hagemeister, Fredrick B.
    Fanale, Michelle A.
    Oki, Yasuhiro
    Shah, Jatin J.
    Thomoas, Sheeba K.
    Hosing, Chitra M.
    Zhang, Liang
    Badillo, Maria
    Chen, Wendy
    Cai, Qingqing
    Zou, Dehui
    Champlin, Richard E.
    Fayad, Luis E.
    Lee, Hun Ju
    Wang, Michael
    BLOOD, 2015, 126 (23)
12345